Advertisement
Advertisement
U.S. Markets close in 2 hrs 19 mins
Advertisement
Advertisement
Advertisement
Advertisement

Alimera Sciences, Inc. (ALIM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
4.2100-0.1200 (-2.77%)
As of 04:00PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.3300
Open4.1700
Bid4.0500 x 800
Ask4.4000 x 1000
Day's Range4.0795 - 4.3344
52 Week Range3.9400 - 12.2500
Volume13,414
Avg. Volume60,856
Market Cap29.21M
Beta (5Y Monthly)1.65
PE Ratio (TTM)N/A
EPS (TTM)-0.2000
Earnings DateFeb 22, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.83
  • GlobeNewswire

    Alimera Sciences to Participate in Upcoming January 2022 Investor Conferences

    ATLANTA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that Rick Eiswirth, Alimera’s President and Chief Executive Officer, will participate in two investor conference events in January. Mr. Eiswirth will be presenting at the H.C

  • GlobeNewswire

    Alimera Sciences Welcomes Ophthalmic Strategic Consultant Erin Parsons to Its Board of Directors

    ATLANTA, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces the addition of Erin Parsons to its Board of Directors. Ms. Parsons has more than 20 years of experience working in the ophthalmic industry overseeing scientific strategy, medical communications, advocacy development, a

  • GlobeNewswire

    Alimera Sciences to Participate in Upcoming November 2021 Investor Conferences

    ATLANTA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that Rick Eiswirth, Alimera’s President and Chief Executive Officer, will participate in three investor conference events in November. Mr. Eiswirth will be presenting at the Q4 Investor Summit Conference, November 16-17, 2021

Advertisement
Advertisement